Jim Cramer acknowledges Clover Health as a profitable speculative pick but reaffirms preference for UnitedHealth and CVS for long-term holdings.
Jim Cramer labeled Clover Health Investments (NASDAQ:CLOV) a successful speculative investment after the company reported GAAP profitability in Q1 2026 and guided for full-year profitability. He noted his earlier stance was not bullish enough but emphasized a stronger long-term outlook for UnitedHealth (UNH) and CVS Health (CVS).
Cramer highlighted that CLOV’s recent quarter was not strong, with revenues described as merely “okay” and earnings lacking. Despite the stock’s upward movement, he cautioned investors to view the gains with skepticism due to the underwhelming quarterly performance.
The discussion occurred during a May 29 episode of *Mad Money*, where Cramer reiterated his focus on larger, more established healthcare stocks over speculative plays like CLOV.